Mark Ford concentrates his practice in antitrust litigation, representing clients across a variety of industries in private litigation and in responding to government antitrust investigations. He has extensive experience litigating cases at the intersection of antitrust and intellectual property law.
For clients in the pharmaceutical industry, Mr. Ford has litigated matters, and regularly counsels clients, concerning brand-generic settlements as well as defending allegations of sham litigation, Walker Process fraud, and improper “Orange Book” listings. He has represented pharmaceutical companies and their employees in federal court, before the Federal Trade Commission, and in responding to inquiries from the European Commission.
Mr. Ford also has extensive experience litigating matters and advising clients on competition issues arising from the assertion of standard-essential patents (SEPs). He has litigated several SEP antitrust claims in federal courts on behalf of clients alleging that SEP holders have violated commitments to license SEPs on fair, reasonable and non-discriminatory terms. Mr. Ford has also appeared before the Department of Justice to address issues of SEP abuse.
Finally, Mr. Ford has represented clients from a variety of industries in federal courts and in agency investigations in matters concerning alleged monopolization, price fixing and horizontal mergers.